Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized Clinical Trial of Low and Intermediate Risk OliGometastatic ColoREctal CancEr PatieNts Treated with Stereotactic ABlative Radiotherapy: GREEN LaIT-SABR Study

NCT06310564 is registered in ClinicalTrials.gov with IRCCS Sacro Cuore Don Calabria di Negrar as lead sponsor.

NCT NCT06310564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06310564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized Clinical Trial of Low and Intermediate Risk OliGometastatic ColoREctal CancEr PatieNts Treated with Stereotactic ABlative Radiotherapy: GREEN LaIT-SABR Study
Lead sponsor
IRCCS Sacro Cuore Don Calabria di Negrar
Phase
Not applicable
Overall status
Recruiting
Start date
March 18, 2024
Completion date
April 30, 2031
Enrollment
204 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer